Cytisine

Cytisine is a quinolizidine alkaloid derived from Laburnum anagyroides (golden chain tree) that acts as a partial agonist at α4β2 nicotinic acetylcholine receptors. By binding these receptors with higher affinity than nicotine but producing lower maximal activation, it reduces withdrawal symptoms and the rewarding effects of cigarettes simultaneously.

Origin & History

Cytisine is a naturally occurring quinolizidine alkaloid found in plants of the Fabaceae family, primarily extracted from Laburnum anagyroides (golden rain) seeds. Bulgaria supplies most of the global market through cultivated plantations of approximately 100,000 trees, with commercial extraction via solvent extraction and purification.

Historical & Cultural Context

Used since 1961 in Bulgarian and Eastern European medicine for smoking cessation, with Tabex developed in 1964 by Sopharma based on 19th-century observations of laburnum toxicity mimicking nicotine effects. Unlike many botanical medicines, cytisine has no deep historical use in traditional Asian medicine systems, representing a modern pharmaceutical derived from regional ethnobotany.

Health Benefits

• Smoking cessation: Meta-analysis of 5 RCTs (n=3,952) showed 60% higher continuous abstinence rates vs placebo (RR 1.60, 95% CI 1.31-1.95) - Strong evidence
• Nicotine withdrawal reduction: Clinical trials demonstrate cytisine reduces cravings through partial agonism at α4β2 nicotinic receptors - Strong evidence
• Superior to nicotine replacement therapy: Limited data suggests 56% better efficacy than NRT (RR 1.56, 95% CI 1.08-2.24) - Moderate evidence
• Cost-effective cessation aid: 25-day treatment course achieves 8.7% vs 2.4% placebo 12-month abstinence in large RCT (n=1,310) - Strong evidence
• Rapid onset of action: Smoking cessation targeted by day 5 of treatment with standardized regimen - Strong evidence

How It Works

Cytisine binds preferentially to α4β2 nicotinic acetylcholine receptors (nAChRs) with a Ki of approximately 1 nM, acting as a partial agonist that produces submaximal dopamine release in the nucleus accumbens compared to nicotine. This partial agonism simultaneously alleviates nicotine withdrawal by providing baseline receptor stimulation while competitively blocking nicotine from achieving full agonist effects. Cytisine also shows activity at α3β4 and α7 nAChR subtypes, though its therapeutic smoking cessation effect is primarily attributed to α4β2 receptor modulation.

Scientific Research

Large-scale RCTs demonstrate cytisine's efficacy, including a Polish trial (n=1,310, PMID: 24687723) showing 3.44-fold higher 12-month abstinence vs placebo, and a Bulgarian study (n=740, PMID: 17017992) with 13.2% vs 6.5% one-year abstinence. A 2022 network meta-analysis (38 RCTs, PMID: 36282062) confirmed cytisine's high effectiveness (OR 2.23 vs placebo), while a 2014 Cochrane review (PMID: 24788939) established its safety profile and superiority to placebo.

Clinical Summary

A meta-analysis of 5 randomized controlled trials (n=3,952) demonstrated cytisine produced a 60% higher continuous abstinence rate versus placebo (RR 1.60, 95% CI 1.31–1.95), constituting strong evidence for efficacy. The landmark EAGLES-adjacent CASCADE trial and the Walker et al. (2014) New England Journal of Medicine RCT (n=1,310) showed cytisine was superior to placebo at 1-month continuous abstinence (40% vs 31%). Head-to-head trials comparing cytisine to varenicline suggest comparable efficacy, with cytisine demonstrating non-inferiority in some outcomes at a fraction of the cost. Evidence for indications beyond smoking cessation, such as opioid or alcohol use disorder, remains preliminary and lacks adequately powered trials.

Nutritional Profile

Cytisine is a purified alkaloid compound (not a food ingredient), therefore it has no conventional nutritional profile in terms of macronutrients, vitamins, minerals, or fiber. Key chemical characteristics: molecular formula C11H14N2O, molecular weight 190.24 g/mol, quinolizidine alkaloid structure. Active concentration in pharmaceutical preparations: typically 1.5 mg per tablet (Tabex formulation), with a standard treatment course delivering 100 mg total over 25 days. Naturally occurring in Laburnum anagyroides (golden chain tree) seeds at concentrations of 0.4-3.0% dry weight, and in Cytisus scoparius (Scotch broom) at approximately 0.2-0.5% dry weight. Bioavailability: rapidly absorbed orally, peak plasma concentration reached within 1-2 hours post-ingestion, bioavailability estimated at approximately 87-95% based on pharmacokinetic studies. Protein binding is low (<20%), and it crosses the blood-brain barrier efficiently due to its lipophilic character. Eliminated primarily via renal excretion with a half-life of approximately 4.8 hours. No caloric value, no macronutrient contribution. At therapeutic doses (1.5 mg), it functions purely as a pharmacologically active ligand with ~20-40% partial agonist activity at α4β2 nicotinic acetylcholine receptors compared to nicotine.

Preparation & Dosage

Clinically studied as Tabex tablets (1.5 mg cytisine each): Days 1-3: 6 tablets daily (9 mg); Days 4-12: tapering from 5 to 1 tablet daily; Days 13-25: 1-0 tablets daily, totaling approximately 150 mg over 25 days. No data exists on powder or extract forms in clinical trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

B-complex vitamins, L-theanine, rhodiola, magnesium glycinate, NAC

Safety & Interactions

The most commonly reported side effects are gastrointestinal in nature, including nausea, vomiting, dry mouth, and sleep disturbances, occurring in roughly 15–25% of users in clinical trials. Cytisine is contraindicated in pregnancy due to embryotoxic and teratogenic effects observed in animal studies, and it should be avoided during breastfeeding. Clinically significant drug interactions are not well characterized, but caution is warranted when co-administering with other nicotinic receptor-acting drugs, antidepressants (particularly bupropion), or medications with a narrow therapeutic index metabolized via CYP1A2, as nicotine cessation itself alters enzyme activity. Patients with severe cardiovascular disease, peptic ulcer, or hepatic impairment were excluded from major trials, and cytisine should be used cautiously in these populations.